Paratek Pharmaceuticals, Inc. (PRTK) Forecasted to Earn FY2017 Earnings of ($3.05) Per Share
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) – Equities research analysts at Gabelli lifted their FY2017 earnings estimates for Paratek Pharmaceuticals in a report issued on Thursday. Gabelli analyst K. Kedra now anticipates that the specialty pharmaceutical company will post earnings of ($3.05) per share for the year, up from their previous estimate of ($3.20). Gabelli also issued estimates for Paratek Pharmaceuticals’ FY2018 earnings at ($2.60) EPS, FY2019 earnings at ($3.40) EPS and FY2020 earnings at ($1.85) EPS.
A number of other research analysts have also issued reports on PRTK. Cantor Fitzgerald set a $50.00 target price on Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, July 17th. HC Wainwright increased their target price on Paratek Pharmaceuticals from $36.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday, July 18th. BidaskClub downgraded Paratek Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Zacks Investment Research raised Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a research note on Saturday, August 5th. Finally, Raymond James Financial, Inc. reissued a “strong-buy” rating and issued a $36.00 price objective on shares of Paratek Pharmaceuticals in a research note on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $40.00.
TRADEMARK VIOLATION WARNING: “Paratek Pharmaceuticals, Inc. (PRTK) Forecasted to Earn FY2017 Earnings of ($3.05) Per Share” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/11/14/paratek-pharmaceuticals-inc-prtk-forecasted-to-earn-fy2017-earnings-of-3-05-per-share.html.
Paratek Pharmaceuticals (PRTK) opened at $21.65 on Monday. Paratek Pharmaceuticals has a 52-week low of $12.55 and a 52-week high of $29.00. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.49.
A number of hedge funds and other institutional investors have recently bought and sold shares of PRTK. C WorldWide Group Holding A S raised its stake in Paratek Pharmaceuticals by 449.3% in the 2nd quarter. C WorldWide Group Holding A S now owns 439,400 shares of the specialty pharmaceutical company’s stock valued at $10,590,000 after purchasing an additional 359,400 shares during the last quarter. Pictet Asset Management Ltd. acquired a new stake in shares of Paratek Pharmaceuticals in the 2nd quarter worth $6,957,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Paratek Pharmaceuticals in the 3rd quarter worth $8,598,000. State Street Corp increased its stake in shares of Paratek Pharmaceuticals by 112.3% in the 2nd quarter. State Street Corp now owns 616,112 shares of the specialty pharmaceutical company’s stock worth $14,850,000 after acquiring an additional 325,856 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Paratek Pharmaceuticals by 275.9% in the 1st quarter. Renaissance Technologies LLC now owns 414,513 shares of the specialty pharmaceutical company’s stock worth $7,979,000 after acquiring an additional 304,249 shares during the last quarter. 82.46% of the stock is owned by hedge funds and other institutional investors.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Stock Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.